Trial Profile
An Open-Label, Multicenter, Nonrandomized, Dose-Escalation and Tumor-Expansion Phase 1 Study to Evaluate the Safety and Tolerability of INCSHR01210 (Formerly SHR-1210) in Subjects With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Camrelizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Atridia; Incyte Biosciences International; Incyte Corporation
- 07 Aug 2019 Status changed from active, no longer recruiting to completed.
- 19 Feb 2019 Planned End Date changed from 1 May 2019 to 1 Sep 2029.
- 19 Feb 2019 Planned primary completion date changed from 1 Nov 2018 to 1 Mar 2020.